Floatz logo

Therapeutic Asset Ratings

13,145 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Entinostat
Lymphoma
National Cancer Institute (NCI)P2B (57)
Epcoritamab
B-Cell Non-Hodgkin Lymphoma
Mwanasha Merrill, MDP2B (57)
Epcoritamab
Non-Hodgkin Lymphoma
Mwanasha Merrill, MDP2B (57)
Epinephrine
Post-Operative Pain, Non-Human Animal
IVO JURISICP2B (57)
Eribulin/Farletuzumab Antibody Drug Conjugate
Ovarian Neoplasm
Bristol-Myers SquibbP2B (57)
Etoposide
Ovarian Carcinoma
Fudan UniversityP2B (57)
Etrumadenant
Lung Cancer
Gilead SciencesP2B (57)
Everolimus
Pancreatic Neuroendocrine Tumor G1
AC Camargo Cancer CenterP2B (57)
Exemestane
HER2 Positive Breast Carcinoma
Fudan UniversityP2B (57)
Exemestane
Prostate Cancer
OHSU Knight Cancer InstituteP2B (57)
Ezabenlimab
Metastatic Malignant Neoplasm
Boehringer IngelheimP2B (57)
Ezabenlimab
Neoplasm
Boehringer IngelheimP2B (57)
Famitinib
Small Cell Lung Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP2B (57)
FAPI74
Cholangiocarcinoma
National Cancer Institute (NCI)P2B (57)
FAPI74
Colorectal Cancer
SOFIEP2B (57)
FAPI74
Gastric Cancer
National Cancer Institute (NCI)P2B (57)
FAPI74
Digestive System Cancer
SOFIEP2B (57)
FAPI74
Hepatocellular Carcinoma
National Cancer Institute (NCI)P2B (57)
FAPI74
Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)P2B (57)
Favezelimab
Skin Squamous Cell Carcinoma
Merck Sharp & Dohme LLCP2B (57)
Favezelimab
Endometrial Carcinoma
Merck Sharp & Dohme LLCP2B (57)
Fenofibrate
Breast Carcinoma
Tanta UniversityP2B (57)
Fenofibrate
Metabolic Dysfunction-Associated Steatotic Liver Disease
Yokohama City UniversityP2B (57)
Fepixnebart
Diabetic Neuropathy
Eli Lilly and CompanyP2B (57)
Fexagratinib
Lymphoma
National Cancer Institute (NCI)P2B (57)
Showing 3076 to 3100 of 13,145 assets
PreviousPage 124 of 526Next